This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?
by Zacks Equity Research
Here is how Cabaletta Bio, Inc. (CABA) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
by Zacks Equity Research
QIAGEN's (QGEN) NGS interpretation software, QCI Interpret, now covers the whole exome due to additional AI capabilities.
What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Cabaletta Bio, Inc. (CABA) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Wall Street Analysts Believe Cabaletta Bio, Inc. (CABA) Could Rally 41.61%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 41.6% upside potential for Cabaletta Bio, Inc. (CABA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Recent Price Trend in Cabaletta Bio, Inc. (CABA) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Cabaletta Bio, Inc. (CABA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Does Cabaletta Bio, Inc. (CABA) Have the Potential to Rally 27.85% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 27.9% in Cabaletta Bio, Inc. (CABA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Cabaletta Bio, Inc. (CABA) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Cabaletta Bio, Inc. (CABA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Novo Nordisk (NVO) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Novo Nordisk (NVO) reports mixed results for Q4 as earnings beat estimates but sales miss on the same. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Is Aurora Cannabis (ACB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aurora Cannabis Inc. (ACB) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Cabaletta Bio, Inc. (CABA) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences
by Zacks Equity Research
AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog.
4 Drug Stocks That More Than Doubled This Year
by Zacks Equity Research
We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.
Is Neuronetics (STIM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Neuronetics (STIM) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Can Cabaletta Bio, Inc. (CABA) Climb 60% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Cabaletta Bio, Inc. (CABA) points to a 60% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Merck & Co. (MRK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Merck (MRK) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
What Makes Cabaletta Bio, Inc. (CABA) a New Buy Stock
by Zacks Equity Research
Cabaletta Bio, Inc. (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down 63.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Cabaletta Bio, Inc. (CABA)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Cabaletta Bio, Inc. (CABA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Wall Street Analysts Predict a 52% Upside in Cabaletta Bio, Inc. (CABA): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Cabaletta Bio, Inc. (CABA) points to a 51.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks.com featured highlights include: UFP Industries, Cabaletta Bio, Alto Ingredients, Ribbon Communications and Software Acquisition Group
by Zacks Equity Research
Zacks.com featured highlights include: UFP Industries, Cabaletta Bio, Alto Ingredients, Ribbon Communications and Software Acquisition Group
5 Stocks for Solid Returns as Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like UFP Industries (UFPI), Cabaletta Bio (CABA), Alto (PEIX), Ribbon (RBBN) and Software Acquisition (CURI).
Cabaletta Bio, Inc. (CABA) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Cabaletta Bio, Inc. (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for April 27th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Cabaletta Bio, Inc. (CABA) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Cabaletta Bio, Inc. (CABA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.